FDA clears Avantis digital scope for colon polyp detection
Avantis Medical Systems, a developer of chip-on-catheter digital imaging devices, reported that its Third Eye Retroscope for the detection of cancerous and pre-cancerous colon polyps has received FDA 510(k) clearance.
The Third Eye Retroscope is indicated for use with colonoscopy to provide the physician with an additional view of the colon for diagnostic and detection purposes. This is the first technology that has been cleared by the FDA to enhance polyp detection when used in conjunction with colonoscopy, according to the Sunnyvale, Calif.-based company.
When the Third Eye is deployed through the instrument channel of a standard colonoscope, it provides the physician with a retrograde view of the colon along with the forward view, Avantis said. Operating as a "rear view mirror," the Third Eye helps visualize blind spots in the colon that may not be seen with the colonoscope alone. The device now is commercially available to physicians who perform colonoscopies.
The Third Eye Retroscope is indicated for use with colonoscopy to provide the physician with an additional view of the colon for diagnostic and detection purposes. This is the first technology that has been cleared by the FDA to enhance polyp detection when used in conjunction with colonoscopy, according to the Sunnyvale, Calif.-based company.
When the Third Eye is deployed through the instrument channel of a standard colonoscope, it provides the physician with a retrograde view of the colon along with the forward view, Avantis said. Operating as a "rear view mirror," the Third Eye helps visualize blind spots in the colon that may not be seen with the colonoscope alone. The device now is commercially available to physicians who perform colonoscopies.